1. Your patent on drug A expires
2. You have an active patent monopoly on drug B which is functionally similar
3. You use your giant network of marketing staff to convince medical professionals to use B instead of A
4. The market for A collapses due to lack of demand.
The generics manufacturers cannot afford to spend nearly as much bribing doctors, so you don't get an equivalent demand push for generics unless one of the competing large pharma groups decide that the generic is profitable enough to counter the targeted campaign with a targeted campaign of their own. But why would they, when they can milk their own patent monopoly cashcows a bit more using the same marketing spend.
(My foot is fine, I got a cold, yay hospitals)
Doctor's inboxes are filled with emails from drug company reps offering to take them out to play golf and fancy dinners and give them boxes of free samples of the drugs made by the companies they rep. Those companies don't sell the low cost generics!
(source: a relative of mine is a drug company rep!)
I'd want to hire people who are knowledgeable about pharmaceuticals and are able to accurately and intelligently answer questions about research studies and side effects. But an effective person would probably hire hot chicks and chatty dudes and give them big expense accounts.
Yes, the original manufacturer often spends money to develop follow on versions that can qualify for new patents, but this isn't always an effective strategy. When it is, it's usually because the follow on version has substantial benefits for patients (e.g., monthly infusions at the doctor's office instead of weekly). If those benefits aren't there, insurers can and will decline to cover the new form of the drug and insist on the generic.
[1] http://www.nytimes.com/2013/03/19/business/use-of-generics-p...
If they abandon it, and no generic is produced, patients are forced to the patented alternatives.
The drug companies don't want to compete with their own products if they can avoid doing so.
The different outcomes are largely explained thus:
Drugs with a very large demand and especially ones which are OTC and around which consumer brands can be developed (where brand identity allows a premium to be charged, substituting in some degree for the monopoly rents patents allow) are likely to continue to be manufactured after patents expire. Prescription drugs with a limited demand even if they are the best (or only) effective treatment for a particular condition are less likely to continue to be produced once patent protection expires..